Fluvoxamine is a member of the selective serotonin reuptake inhibitor (SSRI) family of drugs. Initially manufactured by Duphar Laboratories in the United Kingdom in 1971, fluvoxamine was registered as an antidepressant in Switzerland in 1983, becoming the first drug in the now hugely popular SSRI class to reach the market (Freeman 1991). Since its introduction, fluvoxamine has undergone a wide range of trials to assess its therapeutic potential in depression and across several anxiety disorders, including obsessive-compulsive disorder (OCD). Fluvoxamine has been available in the United States since 1994, when it received U.S. Food and Drug Administration (FDA) approval for the treatment of OCD (Ware 1997). More than 28 million people worldwide have been treated with fluvoxamine (Buchberger and Wagner 2002).